ELOIRA 52MG/IUD INTRA UTERINE DEVICE

Indications

• Prevention of pregnancy
• Management of menstrual disorders
• Regulation of the menstrual cycle
• Treatment of endometriosis
• Acne treatment in females

Dosage

Children: Refer to BNF for Children for appropriate dosing and recommendations, particularly

Adults: Refer to specific product guidelines and BNF for appropriate dosage based on the type of contraceptive used. For oral contraceptives, typical dosing involves taking one pill daily at the same time for 21 days followed by a 7-day break.

Mechanism of action

Hormonal contraceptives primarily work by suppressing ovulation through the inhibition of gonadotropin secretion from the pituitary gland. They also thicken cervical mucus, making it difficult for sperm to enter the uterus, and alter the endometrial lining to prevent implantation. Non-hormonal methods like copper IUDs create an inflammatory reaction that is toxic to sperm and eggs, preventing fertilization.

Pharmacodynamics

The pharmacodynamics of contraceptives involve the modulation of hormonal pathways that regulate the menstrual cycle. Estrogens and progestins lead to changes in the hypothalamic-pituitary-gonadal axis, reducing the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which are crucial for ovulation. Additionally, changes in endometrial receptivity and cervical mucus provide further mechanisms of action.

Pharmacokinetics

The pharmacokinetics of hormonal contraceptives vary depending on the formulation. Oral contraceptives are typically absorbed in the gastrointestinal tract, with peak plasma concentrations occurring within 1 to 4 hours. They undergo hepatic metabolism, primarily via cytochrome P450 enzymes, and are excreted in urine and feces. The half-life can range from several hours to a few days, depending on the specific hormone. Non-hormonal methods do not undergo systemic absorption.

Contra-indications

• Pregnancy
• History of thromboembolic disorders
• Severe hypertension
• Liver tumors or active liver disease
• Known or suspected breast cancer
• Undiagnosed abnormal genital bleeding

Adverse effects

• Nausea
• Vomiting
• Headache
• Mood changes
• Breast tenderness
• Weight gain
• Increased risk of thromboembolism

Interactions

• Antibiotics (e.g., rifampicin) may reduce efficacy
• Anticonvulsants (e.g., phenytoin, carbamazepine) may reduce efficacy
• St. John's Wort may reduce efficacy
• Certain antifungals may increase estrogen levels

Precautions

• Monitor for signs of thromboembolic events
• Consider alternative contraception in women with a history of migraines
• Assess cardiovascular risk factors regularly
• Use caution in women with diabetes or liver disease

Pregnancy

Contraceptives are contraindicated during pregnancy and should not be used in pregnant individuals.

Breast-feeding

Some hormonal contraceptives may affect milk production; consult healthcare provider for recommendations.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

• Combination oral contraceptives (estrogen and progestin)
• Progestin-only pills
• Transdermal patches
• Vaginal rings
• Injectable contraceptives
• Intrauterine devices (IUDs)

Indications

• Hypogonadism
• Menopause symptoms
• Hormone-sensitive cancers (e.g., breast, prostate)
• Endocrine disorders (e.g., thyroid dysfunction)
• Contraception
• Hormonal replacement therapy

Dosage

Children: Paediatric dosing is highly specific to the drug and condition being treated. Refer to paediatric pharmacology references for guidance.

Adults: Dosage varies widely based on the specific hormonal drug, indication, and patient factors. Refer to the appropriate clinical guidelines and formularies for specific dosing recommendations.

Mechanism of action

Hormonal drugs exert their effects by binding to specific hormone receptors on target cells, altering gene expression and cellular function. This can lead to changes in metabolic pathways, growth regulation, and other physiological responses. The exact mechanism can vary significantly depending on the specific hormone or hormone analogue involved.

Pharmacodynamics

The pharmacodynamic effects of hormonal drugs depend on their specific action on hormone receptors. Agonists can activate receptors and mimic the effects of natural hormones, while antagonists can block receptor activation, inhibiting hormone action. The response to hormonal drugs can vary based on receptor sensitivity, the presence of co-regulators, and the hormonal milieu of the individual.

Pharmacokinetics

Hormonal drugs can vary widely in their pharmacokinetics, including absorption, distribution, metabolism, and excretion. For example, some hormones may be rapidly metabolized by the liver, while others may have a longer half-life and be excreted via the kidneys. The route of administration (oral, transdermal, intramuscular, etc.) can also influence these parameters significantly.

Contra-indications

• Hormonal therapy is contraindicated in patients with a history of hormone-sensitive cancers, such as breast or prostate cancer.
• Active liver disease or hepatic impairment.
• Undiagnosed vaginal bleeding.
• Severe uncontrolled hypertension.
• Thromboembolic disorders, including deep vein thrombosis and pulmonary embolism.

Adverse effects

• Nausea and vomiting.
• Breast tenderness or enlargement.
• Mood changes, including depression or anxiety.
• Weight gain or loss.
• Headaches or migraines.
• Increased risk of thromboembolic events.
• Menstrual irregularities.

Interactions

• Anticonvulsants, such as phenytoin and carbamazepine, may decrease the effectiveness of hormonal therapies.
• Antibiotics, particularly rifampicin, can reduce hormonal contraceptive efficacy.
• Certain herbal supplements, such as St. John's Wort, may also interfere with hormonal medications.

Precautions

• Monitor for signs of thromboembolism, especially in patients with risk factors.
• Assess liver function regularly in patients with a history of hepatic issues.
• Use with caution in patients with a history of depression or mood disorders.
• Regular breast examinations and mammograms for women on hormonal therapy.

Pregnancy

Hormonal therapies are generally contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Some hormonal therapies may affect lactation; consult healthcare providers for alternatives.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Oral tablets.
• Transdermal patches.
• Injectable forms.
• Topical gels or creams.

Indications

• Contraception
• Heavy menstrual bleeding
• Endometrial protection in women with risk factors for endometrial hyperplasia
• Management of dysmenorrhea
• Emergency contraception (specific types)

Dosage

Children: The use of intrauterine devices in adolescents should be guided by clinical assessment and specific recommendations from healthcare providers, refer to the BNF for Children for appropriate dosing information.

Adults: Refer to specific product guidelines and the BNF for appropriate dosing instructions based on the type of intrauterine device and clinical indication.

Mechanism of action

The mechanism of action of intrauterine devices, particularly hormonal IUDs, involves the release of hormones such as levonorgestrel, which thickens cervical mucus, inhibits sperm motility, and alters the endometrial lining to prevent implantation. Copper IUDs release copper ions that are toxic to sperm and create a local inflammatory response that is hostile to sperm and eggs.

Pharmacodynamics

The pharmacodynamics of intrauterine devices involve the localized effects within the uterine cavity. Hormonal IUDs lead to changes in the endometrium, making it less receptive to implantation. The local release of hormones also reduces menstrual bleeding and dysmenorrhea. Copper IUDs primarily act by preventing fertilization through their impact on sperm viability and motility.

Pharmacokinetics

Pharmacokinetics varies between hormonal and copper IUDs. Hormonal IUDs release a steady dose of hormone locally, with minimal systemic absorption. The half-life of levonorgestrel in the systemic circulation is about 30 hours. Copper IUDs do not release systemic hormones and their effects are localized. The lifespan of copper IUDs can extend up to ten years, while hormonal IUDs may last for three to five years depending on the specific product.

Contra-indications

• Pregnancy
• Unexplained vaginal bleeding
• Pelvic inflammatory disease
• Uterine or cervical cancer
• Certain uterine abnormalities

Adverse effects

• Menstrual changes
• Pelvic pain
• Expulsion of the device
• Infection
• Uterine perforation

Precautions

• Ensure proper placement by a healthcare professional
• Monitor for signs of infection
• Consider potential for heavy menstrual bleeding
• Assess for risk factors for pelvic inflammatory disease

Pregnancy

Contraindicated during pregnancy. Should not be used if pregnancy is confirmed or suspected.

Breast-feeding

Generally considered safe, but consult a healthcare provider for individual circumstances.

Storage

Store at room temperature, away from moisture and direct sunlight. Follow specific storage instructions provided by the manufacturer.

Formulations

• Copper intrauterine device (IUD)
• Levonorgestrel-releasing intrauterine system (IUS)

Dosage

Children: Refer to specific drug information for appropriate dosing.

Adults: Refer to specific drug information for appropriate dosing.

Mechanism of action

Systemic medications typically work by entering the bloodstream and interacting with specific receptors or enzymes in various tissues, leading to a therapeutic effect. For example, antibiotics may inhibit bacterial cell wall synthesis, while analgesics may block pain receptors in the central nervous system.

Pharmacodynamics

The pharmacodynamics of systemic drugs depend on their specific class and mechanism of action. Generally, systemic drugs are intended to provide widespread effects across the body, which can lead to both therapeutic effects and potential side effects. The efficacy of these drugs is often measured by their ability to achieve desired plasma concentrations that correlate with clinical outcomes.

Pharmacokinetics

Pharmacokinetics of systemic medications involves absorption, distribution, metabolism, and excretion (ADME). After administration, systemic drugs are absorbed into the bloodstream, distributed to various tissues, metabolized by the liver or other organs, and then excreted, primarily through the kidneys. The half-life and clearance rates can vary significantly depending on the drug's chemical properties and the patient's physiology.

Pregnancy

Consult with a healthcare professional before use, as safety in pregnancy has not been established for all drugs.

Breast-feeding

Consult with a healthcare professional before use, as some drugs may pass into breast milk.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.